Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 178

Sort by

Sort Order Select

Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Blood (2025) 146 (Supplement 1): 921.

https://doi.org/10.1182/blood-2025-921

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Ciara Louise Freeman, Sarah Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Johanna Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel

Blood (2025) 146 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2025-4079

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Noemie Leblay, Sungwoo Ahn, Alexandra Poos, Mehmet Samur, Sheri Skerget, Holly Lee, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Daniel Penaherrera, Herve Avet-Loiseau, Jonathan Keats, Nikhil Munshi, Niels Weinhold, Nizar Bahlis, Paola Neri

Blood (2025) 146 (Supplement 1): 2163.

https://doi.org/10.1182/blood-2025-2163

Published: 2025

Journal Articles

Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death

Jiye Liu, Jingyu Xu, Teru Hideshima, Kenneth Wen, Yuntong Liu, Nikhil Munshi, Lijie Xing, Gang An, Kenneth Anderson

Blood (2025) 146 (Supplement 1): 2153.

https://doi.org/10.1182/blood-2025-2153

Published: 2025

Journal Articles

The unique role of PSMD2/Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance

Ting Du, Yuntong Liu, Minxing Wang, Teng Fang, Jingyu Xu, Kenneth Wen, Xueping Wan, Arghya Ray, Sindhu Pillai, Md Abu Musa, Mariateresa Fulciniti, Nikhil Munshi, Yan Song, Kenneth Anderson

Blood (2025) 146 (Supplement 1): 2148.

https://doi.org/10.1182/blood-2025-2148

Published: 2025

Journal Articles

Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis.

Anna Besschetnova, Francesco Ladisa, Anais Schavgoulidze, Shuhui Deng, Eugenio Morelli, Mehmet Samur, Lucy Ort, Christopher Nardone, Xin Gu, Mariateresa Fulciniti, Nikhil Munshi

Blood (2025) 146 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2025-2147

Published: 2025

Journal Articles

Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study

Maya Abdallah, June Corrigan, John Culnan, Danne Elbers, Chibuzor Eze-nwosu, Britney Bell, Nhan Do, Nikhil Munshi, Clark DuMontier, Nathanael Fillmore, Camille Edwards

Blood (2025) 146 (Supplement 1): 2808.

https://doi.org/10.1182/blood-2025-2808

Published: 2025

Journal Articles

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Jackson Smith, Mehmet Samur, Srikanth Talluri, Domenico Maisano, Michela Cumerlato, Charlotte Royer, Fatima Zohura, Sherry Wong, Gareth Morgan, Vaishali Sanchorawala, Nikhil Munshi, Raphael Szalat

Blood (2025) 146 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2025-3923

Published: 2025

Journal Articles

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Blood (2025) 146 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2025-3921

Published: 2025

Journal Articles

Artificial intelligence/machine learning-based risk prediction model guiding individualized interventions to improve outcomes for patients with multiple myeloma

Stuart Sommers, Chunlei Zheng, June Corrigan, John Culnan, Geethika Bodanapu, Grace Ferri, Britney Bell, Meghana Yellanki, Danne Elbers, Nhan Do, Mary Brophy, Nikhil Munshi, Camille Edwards, Nathanael Fillmore

Blood (2025) 146 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2025-4589

Published: 2025

Journal Articles

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Zohaib Ahmed, Walid Hamouche, Shonali Midha, Yuxin Liu, Adam Sperling, Clifton Mo, Jacob Laubach, Paul Richardson, Nikhil Munshi, Omar Nadeem

Blood (2025) 146 (Supplement 1): 7525.

https://doi.org/10.1182/blood-2025-7525

Published: 2025

Journal Articles

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Blood (2025) 146 (Supplement 1): 582.

https://doi.org/10.1182/blood-2025-582

Published: 2025

Journal Articles

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Narsis Attar, Rajib Shome, Mehmet Samur, Joshua Gustine, Charlotte Graham, Kathleen ME Gallagher, Agustin Busse, Deshea L Harris, Diana Cirstea, Andrew Yee, Andrew Branagan, Marcela Maus, Matthew Frigault, Nikhil Munshi, Adam Sperling, Noopur Raje

Blood (2025) 146 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2025-5764

Published: 2025

Journal Articles

Genomic determinants and differences of primary and secondary plasma cell leukemia

Mehmet Samur, Hamza Hassan, Qi Yan, Sarah Parker, Prashant Singh, Megan Schaefer, Kristina Slemmer, Kimberly Celotto, Ian Lund, Hailey Battaglia, Annmarie Nowak, Linda Lutgen, Saeed Daneshmandi, Kenan Onel, Philip McCarthy, Nikhil Munshi, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (Supplement 1): 7469.

https://doi.org/10.1182/blood-2025-7469

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma

Blood (2025) 146 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2025-1032

Published: 2025

Journal Articles

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Blood (2025) 146 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2025-3930

Published: 2025

Journal Articles

Real-world outcomes of newly diagnosed multiple myeloma patients in the veterans affairs healthcare system

Alexander Lazzaro, Kaelyn Nannini, Cenk Yildirim, Linden Huhmann, John Culnan, June Corrigan, Danne Elbers, Nhan Do, Mary Brophy, Nikhil Munshi, Nathanael Fillmore, Camille Edwards

Blood (2025) 146 (Supplement 1): 3979.

https://doi.org/10.1182/blood-2025-3979

Published: 2025

Journal Articles

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Rajib Shome, Srikanth Talluri, Diana Cirstea, Rie Matsubara, Farah Rexha, Advait Joshi, Andrew Yee, Nikhil Munshi, Mehmet Samur, Noopur Raje

Blood (2025) 146 (Supplement 1): 3952.

https://doi.org/10.1182/blood-2025-3952

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death

The unique role of PSMD2/Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance

Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis.

Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Artificial intelligence/machine learning-based risk prediction model guiding individualized interventions to improve outcomes for patients with multiple myeloma

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Genomic determinants and differences of primary and secondary plasma cell leukemia

The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Real-world outcomes of newly diagnosed multiple myeloma patients in the veterans affairs healthcare system

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only